Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe

Mécanismes d’attraction du financement pour l’innovation liée aux antibiotiques: des opportunités pour l’Europe

Christine Årdal (), Yohann Lacotte and Marie-Cécile Ploy
Additional contact information
Christine Årdal: NIPH - Norwegian Institute of Public Health [Oslo]
Yohann Lacotte: RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques - CHU Limoges - INSERM - Institut National de la Santé et de la Recherche Médicale - GEIST - Institut Génomique, Environnement, Immunité, Santé, Thérapeutique - UNILIM - Université de Limoges, RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques - CHU Limoges - INSERM - Institut National de la Santé et de la Recherche Médicale - ΩHealth - OmégaHealth - UNILIM - Université de Limoges
Marie-Cécile Ploy: RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques - CHU Limoges - INSERM - Institut National de la Santé et de la Recherche Médicale - GEIST - Institut Génomique, Environnement, Immunité, Santé, Thérapeutique - UNILIM - Université de Limoges, RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques - CHU Limoges - INSERM - Institut National de la Santé et de la Recherche Médicale - ΩHealth - OmégaHealth - UNILIM - Université de Limoges

Post-Print from HAL

Abstract: Abstract Antibiotic innovation is in serious jeopardy as companies continue to abandon the market due to a lack of profitability. Novel antibiotics must be used sparingly to hinder the spread of resistance, but small companies cannot survive on revenues that do not cover operational costs. When these companies either go bankrupt or move onto other therapeutic areas, these antibiotics may be no longer accessible to patients. Although significant research efforts have detailed incentives to stimulate antibiotic innovation, little attention has been paid to the financing of these incentives. In this article, we take a closer look at 4 potential financing models (diagnosis-related group carve-out, stewardship taxes, transferable exclusivity voucher, and a European-based "pay or play" model) and evaluate them from a European perspective. The attractiveness of these models and the willingness for countries to test them are currently being vetted through the European Joint Action on AMR and Healthcare-Associated Infections (EU-JAMRAI).

Keywords: antibiotic resistance; economic incentives; pull incentives; antimicrobials (search for similar items in EconPapers)
Date: 2020-10-15
References: Add references at CitEc
Citations:

Published in Clinical Infectious Diseases, 2020, 71 (8), pp.1994-1999. ⟨10.1093/cid/ciaa153⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04315532

DOI: 10.1093/cid/ciaa153

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().